All patients
age >= 55 yr age >= 60 yr age >= 65 yr autoimmune disease corticosteroids: no corticosteroids: yes critical disease invasive ventilation no oxygen needed non invasive oxygen omicron variant BA.1 (B.1.1.529) severe disease solid organ transplant recipients subjects at risk
anti-inflammatoty and immuno-therapy in COVID 19 outpatients - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results C3PO, 2020 5.02 [0.58; 43.27]
Clemency, 2021 1.03 [0.02; 52.20]
COMET-ICE, 2021 0.25 [0.01; 5.55]
CoV-Early (Gharbharan), 2022 1.01 [0.06; 16.25]
Ezer N (CONTAIN), 2021 0.93 [0.02; 47.48]
PRINCIPLE (COLCHICINE), 2021 0.42 [0.01; 12.75]
1.21 [0.36 ; 4.13 ] C3PO, 2020, Clemency, 2021, COMET-ICE, 2021, CoV-Early (Gharbharan), 2022, Ezer N (CONTAIN), 2021, PRINCIPLE (COLCHICINE), 2021 6 0% 2,876 moderate not evaluable deathsdetailed results BLAZE-1 phase 3 (combo), 2021 0.05 [0.00; 0.84]
C3PO, 2020 5.02 [0.58; 43.27]
Clemency, 2021 1.03 [0.02; 52.20]
COLCORONA, 2021 0.56 [0.19; 1.66]
COMET-ICE, 2021 0.25 [0.01; 5.55]
CONV-ERT, 2021 0.20 [0.01; 4.07]
Cov-2067 Weinreich (1200mg) Cohort 1, 2020 0.45 [0.05; 3.82]
Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 1.01 [0.02; 51.05]
CoV-Early (Gharbharan), 2022 1.01 [0.06; 16.25]
Ezer N (CONTAIN), 2021 0.93 [0.02; 47.48]
PRINCIPLE (COLCHICINE), 2021 0.42 [0.01; 12.75]
0.58 [0.29 ; 1.18 ] BLAZE-1 phase 3 (combo), 2021, C3PO, 2020, Clemency, 2021, COLCORONA, 2021, COMET-ICE, 2021, CONV-ERT, 2021, Cov-2067 Weinreich (1200mg) Cohort 1, 2020, Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021, CoV-Early (Gharbharan), 2022, Ezer N (CONTAIN), 2021, PRINCIPLE (COLCHICINE), 2021 11 0% 11,728 low low hospitalization or deathdetailed results BLAZE-1 phase 2 (combination with etesevimab), 2020 0.15 [0.02; 1.18]
BLAZE-1 phase 2 (monotherapy), 2020 0.16 [0.02; 1.31]
BLAZE-1 phase 3 (combo), 2021 0.29 [0.15; 0.58]
C3PO, 2020 0.91 [0.63; 1.33]
Clemency, 2021 0.39 [0.09; 1.67]
COLCORONA, 2021 0.79 [0.61; 1.03]
COMET-ICE, 2021 0.21 [0.09; 0.49]
Cov-2067 Weinreich (1200mg) Cohort 1, 2020 0.29 [0.12; 0.68]
PRINCIPLE, 2021 0.81 [0.58; 1.13]
PRINCIPLE (COLCHICINE), 2021 1.29 [0.36; 4.67]
0.52 [0.36 ; 0.76 ] BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020, BLAZE-1 phase 3 (combo), 2021, C3PO, 2020, Clemency, 2021, COLCORONA, 2021, COMET-ICE, 2021, Cov-2067 Weinreich (1200mg) Cohort 1, 2020, PRINCIPLE, 2021, PRINCIPLE (COLCHICINE), 2021 10 67% 11,449 moderate critical clinical deteriorationdetailed results COMET-ICE, 2021 0.24 [0.10; 0.56]
0.24 [0.10 ; 0.56 ] COMET-ICE, 2021 1 0% 1,057 NA not evaluable clinical improvementdetailed results PRINCIPLE, 2021 1.21 [1.08; 1.36]
1.21 [1.08 ; 1.36 ] PRINCIPLE, 2021 1 0% 1,779 NA not evaluable clinical improvement (14-day)detailed results Clemency, 2021 1.19 [0.78; 1.81]
1.19 [0.78 ; 1.81 ] Clemency, 2021 1 0% 400 NA not evaluable clinical improvement (28-day)detailed results Clemency, 2021 1.28 [0.84; 1.96]
1.28 [0.84 ; 1.96 ] Clemency, 2021 1 0% 400 NA not evaluable clinical improvement (7-day)detailed results Clemency, 2021 0.92 [0.51; 1.66]
0.92 [0.51 ; 1.66 ] Clemency, 2021 1 0% 400 NA not evaluable hospitalizationdetailed results C3PO, 2020 0.88 [0.57; 1.34]
COLCORONA, 2021 0.79 [0.60; 1.04]
COMET-ICE, 2021 0.20 [0.08; 0.48]
CONV-ERT, 2021 1.05 [0.78; 1.41]
Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.08 [0.00; 1.49]
CoV-Early (Gharbharan), 2022 0.61 [0.28; 1.33]
Ezer N (CONTAIN), 2021 1.92 [0.47; 7.89]
PRINCIPLE (COLCHICINE), 2021 1.73 [0.43; 7.07]
0.77 [0.54 ; 1.09 ] C3PO, 2020, COLCORONA, 2021, COMET-ICE, 2021, CONV-ERT, 2021, Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021, CoV-Early (Gharbharan), 2022, Ezer N (CONTAIN), 2021, PRINCIPLE (COLCHICINE), 2021 8 61% 7,516 low not evaluable mechanical ventilationdetailed results C3PO, 2020 1.49 [0.25; 9.02]
COLCORONA, 2021 0.53 [0.25; 1.11]
PRINCIPLE, 2021 1.02 [0.45; 2.33]
0.76 [0.45 ; 1.28 ] C3PO, 2020, COLCORONA, 2021, PRINCIPLE, 2021 3 0% 6,489 low not evaluable symptomatic Covid-19detailed results Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.56 [0.31; 1.00]
0.56 [0.31 ; 1.00 ] Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 1 0% 204 NA not evaluable viral clearance detailed results BLAZE-1 phase 2 (combination with etesevimab), 2020 1.65 [0.91; 3.00]
BLAZE-1 phase 2 (monotherapy), 2020 0.67 [0.33; 1.38]
1.08 [0.45 ; 2.60 ] BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020 2 72% 470 moderate not evaluable viral clearance by day 7detailed results BLAZE-1 phase 2 (combination with etesevimab), 2020 1.31 [0.61; 2.83]
BLAZE-1 phase 2 (monotherapy), 2020 0.91 [0.39; 2.09]
Feld, 2021 4.12 [1.08; 15.71]
1.45 [0.70 ; 2.99 ] BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020, Feld, 2021 3 44% 549 moderate not evaluable ICU admissiondetailed results PRINCIPLE, 2021 0.54 [0.24; 1.21]
0.54 [0.24 ; 1.21 ] PRINCIPLE, 2021 1 0% 1,491 NA not evaluable recoverydetailed results Ezer N (CONTAIN), 2021 1.25 [0.71; 2.22]
PRINCIPLE, 2021 1.21 [1.08; 1.36]
PRINCIPLE (COLCHICINE), 2021 0.92 [0.72; 1.17]
1.10 [0.90 ; 1.35 ] Ezer N (CONTAIN), 2021, PRINCIPLE, 2021, PRINCIPLE (COLCHICINE), 2021 3 52% 4,275 moderate not evaluable emergent treatment-resistant variantsdetailed results BLAZE-1 phase 2 (combination with etesevimab), 2020 0.18 [0.02; 1.51]
BLAZE-1 phase 2 (monotherapy), 2020 1.52 [0.51; 4.47]
0.64 [0.08 ; 4.94 ] BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020 2 67% 497 moderate not evaluable related AE (TRAE)detailed results COLCORONA, 2021 1.74 [1.50; 2.03]
1.74 [1.50 ; 2.03 ] COLCORONA, 2021 1 0% 4,412 NA not evaluable serious adverse eventsdetailed results COLCORONA, 2021 0.77 [0.60; 1.00]
Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.25 [0.03; 2.23]
0.75 [0.54 ; 1.05 ] COLCORONA, 2021, Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 2 2% 4,723 low not evaluable adverse eventsdetailed results COMET-ICE, 2021 0.91 [0.68; 1.22]
Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.55 [0.34; 0.86]
Ezer N (CONTAIN), 2021 0.82 [0.43; 1.57]
0.76 [0.54 ; 1.06 ] COMET-ICE, 2021, Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021, Ezer N (CONTAIN), 2021 3 43% 1,563 moderate not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-24 20:08 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 97
- treatments: 546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525
- roots T: 290
